as expected Lanstead is ensuring sufficient financial needs to pay the company's essential bills; the sufficient sustenance to ferry I believe until the end of April maximum where inevitably Neuren will have to put down the cards on the table with the publication of the annual report. on that occasion we will know who is in fact the indirect financial backer of Neuren as the actual beneficiary of the off-market sale for the almost 5.5 million of which is reported today in the published financial content.
in citing the wishes of the management to link a partnership in 2018 or the need for a further increase in the share capital, it is very clear the reference to the conversion of options into shares held by most of the executives in question who are triggered automatically by virtue of a partnership or for a Phase 3 start announcement Trofinetide Rett.
from today's announcements I further note that there is a strong willingness, among other things, to keep the market in "expected" mode in the confused range of 3 $ per share; Intent achieved among other things with minimal effort considering the average volumes recorded in the six months passed today that indicate the daily exchange of 0.5% of the total shares therefore almost not to be considered as a technical indicator.
my teacher reasoning further strengthened with today's news is that by April we will have a clear implication of the situation is that the work of Treagus is concentrated in determining and match a congruous value especially on what can express NNZ-2591 which consequently leads straight to a complete acquisition of the company.
this patent is the key to everything; the dates and the contents compared with the most significant historical activities of the market give brightness to my theory.
https://patents.google.com/patent/US8496963
(20min delay)